Search Results
Your search for ,maY matches 17183 pages
Showing 1101 - 1150Adding Chemoradiation in Perioperative Gastric Cancer Treatment Improves Pathologic Response Rates Without Survival Benefit
Adding chemoradiation to perioperative chemotherapy improves pathologic complete response rates in patients with resectable gastric cancer but does not extend overall survival, according to data presented at the European Society for Medical Oncology (ESMO) Congress 20241 and published...
Regional, Racial, Economic Disparities in Air Pollution–Related Cancer Risk May Be Improving but Still Persist
Investigators report they have uncovered patterns in the risk of cancer associated with lifetime exposure to air pollution and how this risk may have changed over time, in a recent study published by Hurbain et al in Environmental Science & Technology. The findings could build on the scientific ...
Challenges, Potential of Mesenchymal Stem Cells in Cancer Immunotherapy
Investigators have assessed the potential role of mesenchymal stem cells in cancer treatment in a new review published by Minev et al in Oncotarget. Study Overview and Implications The investigators found that mesenchymal stem cells can naturally target tumors and deliver therapeutic agents...
Toripalimab Plus Chemotherapy in First-Line Therapy for Extensive-Stage Small Cell Lung Cancer
In a Chinese phase III trial (EXTENTORCH) reported in JAMA Oncology, Cheng et al reported that the addition of the immunoglobulin G4 PD-1–blocking antibody toripalimab to first-line chemotherapy with etoposide plus cisplatin or carboplatin (EP) improved progression-free survival among patients with ...
Lenvatinib/Pembrolizumab vs Chemotherapy in Advanced Endometrial Cancer
As reported in Journal of Clinical Oncology by Marth et al, the phase III European Network of Gynaecological Oncological Trial-en9/LEAP-001 study showed no significant differences in progression-free or overall survival with first-line lenvatinib/pembrolizumab vs chemotherapy in patients with...
Could SARS–CoV-2 Be an Oncogenic Agent and Cancer Initiator?
It’s not news that some viruses, including human papillomavirus, human immunodeficiency virus, Epstein-Barr, and hepatitis B, can cause or accelerate the development of cancer. But a recent story in The Washington Post about rare cancers being diagnosed in individuals who had previously been...
Obecabtagene Autoleucel in Adults With B-Cell ALL
A second-generation chimeric antigen receptor (CAR) T-cell therapy may offer a new option for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), an aggressive blood cancer with few treatment options. Results from the phase Ib/II FELIX trial, published by Roddie et al in ...
Poor Diets May Increase Risk of Gastrointestinal Cancer
New research may expand on existing evidence that a healthy diet may protect against gastrointestinal cancers and improve disease outcomes, according to a recent study published by Abebe et al in the European Journal of Nutrition. Background Gastrointestinal cancers including esophageal, gastric,...
Lung Cancer CT Screening May Help to Detect Coronary Artery Disease
Lung cancer screening with low-dose chest computed tomography (CT) may be capable of identifying coronary artery calcium in patients without cardiac symptoms, according to a recent study published by Caires et al in the Canadian Medical Association Journal. Background Lung cancer is currently one...
Evidence-Based Recommendations and Knowledge Gaps Regarding Cardio-Oncology
A recent report highlighted evidence-based recommendations for the prevention, detection, and management of cancer therapy–related cardiovascular toxicity and cardiovascular events in patients with cancer, as well as knowledge gaps. Select considerations are summarized herein. “The European Society ...
Pharmacokinetic Comparison of Aumolertinib, Osimertinib, Gefitinib, and Their Major Metabolites in NSCLC
Researchers may have established an accurate ultraperformance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) method for comparing the pharmacokinetic properties of three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and their major metabolites in mouse...
Study May Illuminate Cause of Common Checkpoint Inhibitor Adverse Effect
Researchers may have uncovered the factors contributing to an increased susceptibility to common infections among patients with cancer receiving checkpoint inhibitors, according to a recent study published by Ogishi et al in Immunity. The findings may provide new insights into immune responses and...
Overall Survival Not Improved With Maintenance Niraparib in Advanced Ovarian Cancer
The final overall survival analysis of the phase III PRIMA trial found no survival benefit for maintenance niraparib over placebo in advanced ovarian cancer. However, the PARP inhibitor continued to exert a sustained progression-free survival benefit, investigators reported at the European Society...
At-Home Testing Kits, Coordinated Outreach May Improve Colorectal Cancer Screening Rates
Researchers have demonstrated that a targeted intervention may increase screening rates in patients who do not adhere to current colorectal cancer screening recommendations, according to a recent study published by Reuland et al in JAMA Network Open. Background Colorectal cancer screening is often...
Peer Support Intervention May Help Improve Psychological Outcomes Among Patients With Cancer in Low-Resource Settings
Researchers have found that the cancer peer support program Stronger Together may provide critical social support to patients with cancer, particularly in low-resource settings in low- and middle-income countries, according to a recent study published by Le et al in JCO Global Oncology. Background...
FDA Approves Oral Liquid Imatinib to Treat Patients With Leukemia and Other Cancer Types
The U.S. Food and Drug Administration (FDA) announced the approval of imatinib (Imkeldi) oral solution, the first oral liquid formulation of the drug to treat certain types of leukemias and other cancers. Background In 2024, an estimated 9,280 patients will be diagnosed with chronic myeloid...
Effect of Myeloma Therapy in a Patient With Monoclonal Gammopathy of Thrombotic Significance
In a letter to the editor in The New England Journal of Medicine, Salmasi et al described identification of monoclonal gammopathy of thrombotic significance (MGTS) in a patient with coronary artery disease and its successful treatment with daratumumab, bortezomib, and dexamethasone (DVd). As...
Adding Temozolomide to Radiation Therapy May Improve Survival in Adults With Low-Grade Gliomas
Both radiation and temozolomide may have meaningful single-modality antitumor activity against slow-growing, low-grade gliomas, according to recent findings presented by Schiff et al at the 2024 Society for Neuro-Oncology Annual Meeting (Abstract LTBK-07) and simultaneously published in...
Novel Hypofractionated Proton-Beam Therapy for Older Patients With Newly Diagnosed Glioblastoma
In a phase II trial reported in The Lancet Oncology, Vora et al found that short-course hypofractionated proton-beam therapy guided by 3,4-dihydroxy-6-[F-18]fluoro-L-phenylalanine (F-18–DOPA) positron-emission tomography (PET) and contrast-enhanced MRI produced good outcomes in patients aged ≥ 65...
PEACE-3: Enzalutamide Plus Radium-223 Significantly Improves Survival in Metastatic Castration-Resistant Prostate Cancer
Initial analysis from the PEACE-3 trial suggests that the addition of radium-223 dichloride to enzalutamide could offer a promising new first-line treatment option for patients with metastatic castration-resistant prostate cancer, according to data presented by lead study author, Silke Gillessen,...
LEAP-012: Combination of Therapies Extends Progression-Free Survival in Intermediate-Stage Hepatocellular Carcinoma
The combination of the VEGF tyrosine kinase inhibitor lenvatinib, the PD-1 inhibitor pembrolizumab, and transarterial chemoembolization (TACE) significantly improved progression-free survival in patients with intermediate-stage hepatocellular carcinoma (HCC) compared with TACE alone, according to...
HypoG-01 Trial: Reducing the Treatment Time for Breast Cancer Nodal Irradiation
A 3-week moderately hypofractionated radiotherapy regimen has been found to be noninferior to the 5-week fractionation when irradiating nodal areas in patients with breast cancer, according to data presented at the European Society for Medical Oncology (ESMO) Congress 2024.1 The 5-year results of...
I-SPY2.2: Dato-DXd Plus Durvalumab Yields High Pathologic Response Rate in Breast Cancer Subset
In the neoadjuvant I-SPY2.2 trial, a treatment strategy including the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), partnered with the PD-L1 inhibitor durvalumab, yielded a high pathologic complete response rate, especially in immune-positive and ‘all-negative’ subtypes.1...
Highlights From the ESMO Congress 2024
The European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona featured several groundbreaking trials with the potential to significantly influence clinical practice. These studies highlighted the benefits of new combination immunotherapy strategies and innovative approaches in the...
Trastuzumab Duocarmazine in Previously Treated HER2-Positive Metastatic Breast Cancer
The studies summarized below were reported online over the past month in The ASCO Post, generating a high number of visitors. For comprehensive reviews of these studies and more, visit ASCOPost.com. Trastuzumab Duocarmazine in Previously Treated HER2-Positive Metastatic Breast Cancer In the phase...
Cancer Has Plagued My Family
My twin brother and I were adopted at 18 months old, so I don’t know the medical history of our biological parents and family. But for certain, cancer has played an integral—and heartbreaking—role in my life. Both of my adoptive parents were diagnosed with genitourinary cancers at relatively early ...
Shared Reflections on the 2024 ASCO Annual Meeting: From Networking to Mentorship and More
In earlier issues of The ASCO Post, we shared unique insights from recipients of the International Development and Education Award (IDEA), whose experiences at the 2024 ASCO Annual Meeting (ASCO24) had a profound impact on their professional and personal growth. Here are more reflections from...
NCCN Guidelines Expanded to Meet Growing Understanding of Hereditary Risk
The National Comprehensive Cancer Network (NCCN) introduced expanded NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) to account for the advanced understanding of hereditary cancer risk in breast, ovarian, pancreatic, and prostate cancers.1 “The recently updated NCCN Guidelines for ...
Impact of Food Insecurity on the Incidence of Hepatocellular Carcinoma
At the 2024 American Association for Cancer Research (AACR) Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, Rebecca D. Kehm, PhD, of Columbia University Mailman School of Public Health, New York, and colleagues presented some of the ...
How Functional and Genomic Precision Medicine Are Getting Closer to Matching Each Patient to the Right Therapy
Functional precision medicine—in which information is obtained from direct perturbations of tumor-derived living cells that enable immediate translatable, personalized data to guide patient therapy—has its roots dating back more than 50 years.1 However, advances in two- and three-dimensional...
CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC
The multicenter phase III -CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...
Healthy Women May Have Aneuploid Epithelial Cells Resembling Breast Cancer
Researchers have found that in healthy women, some breast cells that otherwise appear normal may contain chromosome abnormalities typically associated with invasive breast cancer, according to a recent study published by Lin et al in Nature. The findings challenged conventional thinking on the...
Novel p53-MDM2 Inhibitor Plus Ribociclib Demonstrates Anticancer Activity in Liposarcoma Subset
The p53-MDM2 inhibitor siremadlin given with the CDK4/6 inhibitor ribociclib showed activity in a subset of patients with well-differentiated/dedifferentiated liposarcomas enrolled in the biology-driven adaptive phase II MEGAMOST Ribociclib/HDM201 basket trial.1 MEGAMOST was designed to evaluate...
Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC
Firmonertinib (AST2818; formerly furmonertinib), a novel EGFR inhibitor, has shown activity and tolerability in patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR P loop and aC-helix compressing (PACC) mutations, according to data presented at the International Association for ...
FDA Grants Accelerated Approval to Zanidatamab-hrii for Previously Treated Unresectable or Metastatic HER2-Positive Biliary Tract Cancer
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zanidatamab-hrii (Ziihera), a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer, as detected by an FDA-approved test. The FDA also approved ...
Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma
Georgina V. Long, PhD, MBBS, FRACP, of Melanoma Institute Australia and Royal North Shore and Mater Hospitals, The University of Sydney, and colleagues shared their findings from a pooled analysis of long-term outcomes in advanced melanoma reported in the Journal of Clinical Oncology.1 They found...
Neuro-Oncology Guidelines Reveal How AI Could Improve Brain Cancer Diagnosis, Monitoring, and Treatment
An international, multidisciplinary team of neuro-oncology researchers and physicians has developed new clinical practice recommendations for the use of artificial intelligence (AI) methods to more accurately diagnose, monitor, and treat patients with brain cancer. The guidelines were described in...
Firefighters May Be Exposed to Chemicals Associated With Breast Cancer
Investigators have found that firefighters may face occupational exposures to multiple chemicals that could increase their risk of developing breast cancer, according to a recent study published by Cardona et al in Toxics. Background Prior research has revealed that firefighters have significantly...
Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?
Question: Based on NATALEE and monarchE data, is there still a need for neoadjuvant chemotherapy in hormone receptor (HR)-positive, HER2-negative early breast cancer? Answer: In monarchE trial, the CDK4/6 inhibitor abemaciclib combined with endocrine therapy demonstrated long-term efficacy in...
Suicide-Related Mortality in Male AYA Cancer Survivors
Investigators have found that among all cancer survivors, male adolescents and young adults (AYAs) may have the highest rate of suicide-related mortality, according to a recent study published by Matsuo et al in JAMA Network Open. Cancer is becoming more common among young patients, and cancer...
Determining the Optimal First-Line Management of Advanced Classical Hodgkin Lymphoma
“While clinical trials emphasize improvement in cure rates for patients with advanced classical Hodgkin lymphoma, an important goal is reducing the potential long-term effects of treatment,” commented Iris Isufi, MD, of the Smilow Cancer Hospital and Yale Cancer Center, New Haven, Connecticut, and ...
4-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC
Neoadjuvant chemotherapy with vs without the PD-1 inhibitor nivolumab conferred a higher pathologic complete response rate and long-term event-free survival benefit in Asian patients with resectable non–small cell lung cancer (NSCLC), according to the global phase III CheckMate 816 trial. At the...
New Technique May Allow for Visualization of CAR T Cells Postinjection
The University of Cincinnati Cancer Center announced the launch of a new study funded by a $2.3 million National Cancer Institute (NCI) grant to develop a novel technique to visualize where genetically modified immune cells go after being administered in patients with cancer. Background During...
AI Tool May Detect Cancer Gene Signatures in Biopsy Images
Researchers have developed an artificial intelligence (AI)-powered computational program that may be capable of predicting the activity of thousands of genes within tumor cells based on standard microscopy images of a biopsy, according to a recent study published by Pizurica et al in Nature...
Increase in Young-Onset Pancreatic Cancer May Be Due to Overdiagnosis of Early-Stage Endocrine Cancer
A recent analysis of pancreatic cancer data in young adults (aged 15–39) has found that although there is an increase in incidence, the mortality rate remains stable. According to Patel et al, who published their findings in the Annals of Internal Medicine, the rise in incidence is primarily due to ...
Study Identifies New Approach to Overcome Docetaxel Resistance in Patients With Advanced Prostate Cancer
The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years. However, aside from drug or hormonal therapies, other targets to treat prostate cancer are still necessary to prolong life and slow the progression of...
Neoadjuvant Chemoradiation Followed by Immunochemotherapy and Surgery May Improve Outcomes in Esophageal Cancer
A phase II clinical trial investigating the safety and efficacy of a triple combination of radiation, chemotherapy, and immunotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma found that the therapy was effective in shrinking tumors, allowing for surgery, and ...
Immunotherapy Combination for Cutaneous Melanoma
Presurgical treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab may improve outcomes in patients with stage III cutaneous melanoma, according to a recent study published by Davar et al in Cancer Cell. The findings supported the development of vidutolimod for...
Novel Liquid Biopsies and Cancer Detection
Researchers may have uncovered a novel strategy to detect cancer cells with a liquid biopsy that’s designed to be simpler, faster, and more informational than current methods, according to a recent study published by Walker et al in the nanoscience publication Small. Study Methods and Results In...
Addition of Veliparib to Temozolomide in Newly Diagnosed MGMT-Methylated Glioblastoma
In a phase II/III trial reported in JAMA Oncology, Sarkaria et al found that the addition of veliparib to temozolomide did not improve overall survival in patients with newly diagnosed glioblastoma with MGMT promoter hypermethylation. Study Details In the double-blind Alliance for Clinical Trials...
